FDA ratifies CEL-SCI’s confirmatory study plan for head and neck cancer therapy
After years in development, CEL-SCI’s Multikine has moved one more step closer to regulatory approval, as the company announced plans to run another Phase III study for head and neck cancer patients following discussions with the US Food and Drug …